Prep: Availability of HIV drugs should stabilize in the future
According to the Federal Institute for Drugs and Medical Devices (BfArM), the lack of availability of HIV medication should stabilize significantly in just a few days. The two companies Ratiopharm and Heumann, as approval holders, have confirmed to the authority that they will “make significant quantities of goods available to the market at very short notice,” said a spokesman.
With the person concerned drug This is the so-called pre-exposure prophylaxis, or Prep for short. It protects against HIV infection and is used by tens of thousands of people in Germany.
Recently, several manufacturers reported delivery bottlenecks. According to doctors, some users had to interrupt their intake or change their therapy because of this. Aidshilfe had warned of fatal consequences because the drug is also taken by people who are already suffering from it HIV are infected.
At the beginning of the week, the BfArM announced that availability would only stabilize slightly in February. However, according to current plans, supplies should now last until at least the end of April and be available to supply users.
According to the Federal Institute for Drugs and Medical Devices (BfArM), the lack of availability of HIV medication should stabilize significantly in just a few days. The two companies Ratiopharm and Heumann, as approval holders, have confirmed to the authority that they will “make significant quantities of goods available to the market at very short notice,” said a spokesman.
With the person concerned drug This is the so-called pre-exposure prophylaxis, or Prep for short. It protects against HIV infection and is used by tens of thousands of people in Germany.
